Martínez Olmos M A, Varela J M, Ezquieta B, Hillman N, Díez J J
Servicio de Endocrinología y Nutrición, Hospital Universitario La Paz, Madrid.
Med Clin (Barc). 1997 Oct 4;109(11):421-4.
21-hydroxilase deficiency accounts for over 90% of all cases of congenital adrenal hyperplasia (CAH). There is a non-negligible incidence of both severe and nonclassical forms of this genetic disorder. Enzyme deficiency is due to mutations in the gene encoding adrenal 21-hydroxylase (named CYP 21B) and is inherited in an autosomical recesive way. Complete or partial impairment of enzyme activity has been correlated with the different clinical forms of the disease.
In the present paper CYP 21B gene analysis results obtained in a family with two kindred affected by a nonclassical form of the disease are shown. Clinical assessment of these two kindred showed a very mild form of the disease, whereas biochemical results suggested a late-onset partial 21-hydroxylase deficiency. Genotyping for deletions and 10 point mutations in the CYP 21B gene was performed by Southern blot analysis and polymerase chain reaction (PCR) allele-specific oligonucleotide (ASO) hybridation technique.
Molecular genetic analysis performed in the two affected patients and two further relatives allowed us to detect the presence of different mutations in the two alleles of the CYP 21B gene. One of these mutations was severe (655G) and came from maternal line, whereas the other was mild (Val281Leu) and originated in paternal line.
Molecular genetic analysis allows the possibility of finding severe (and non-expected) mutations in patients with clinically mild and late-onset forms of the 21-hydroxylase deficiency.
21-羟化酶缺乏症占先天性肾上腺皮质增生症(CAH)所有病例的90%以上。这种遗传性疾病的严重和非典型形式的发病率都不可忽视。酶缺乏是由于编码肾上腺21-羟化酶(命名为CYP 21B)的基因突变所致,并且以常染色体隐性方式遗传。酶活性的完全或部分受损与该疾病的不同临床形式相关。
本文展示了在一个有两个亲属受非典型形式疾病影响的家族中获得的CYP 21B基因分析结果。对这两个亲属的临床评估显示疾病形式非常轻微,而生化结果提示为迟发性部分21-羟化酶缺乏。通过Southern印迹分析和聚合酶链反应(PCR)等位基因特异性寡核苷酸(ASO)杂交技术对CYP 21B基因的缺失和10个点突变进行基因分型。
对两名受影响患者和另外两名亲属进行的分子遗传学分析使我们能够检测到CYP 21B基因两个等位基因中存在不同的突变。其中一个突变严重(655G),来自母系,而另一个突变轻微(Val281Leu),起源于父系。
分子遗传学分析使得在临床症状轻微和迟发性21-羟化酶缺乏症患者中发现严重(且意外)突变成为可能。